We are live on ! Find out more
KROS icon

Keros Therapeutics
KROS

129 hedge funds and large institutions have $937M invested in Keros Therapeutics in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 50 increasing their positions, 33 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

53,800% more call options, than puts

Call options by funds: $2.16M | Put options by funds: $4K

52% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 33

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

5.4% more ownership

Funds ownership: 71.7% → 77.1% (+5.4%)

2% more funds holding

Funds holding: 126 → 129 (+3)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

1% less capital invested

Capital invested by funds: $948M → $937M (-$11.2M)

Holders
129
Holders Change
+3
Holders Change %
+2.38%
% of All Funds
2.06%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
20
Increased
50
Reduced
33
Closed
17
Calls
$2.16M
Puts
$4K
Net Calls
+$2.15M
Net Calls Change
-$2.39M

Top Buyers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
+$47M
2
YCM
Yiheng Capital Management
California
+$28M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$26.8M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.8M
5
EAM
Eventide Asset Management
Massachusetts
+$15.2M

Top Sellers

Rank Fund Capital Flow
1
DGM
Darwin Global Management
Jersey
-$20.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.9M
3
Millennium Management
Millennium Management
New York
-$7.92M
4
SFM
Sphera Funds Management
Israel
-$6.5M
5
SCM
Soleus Capital Management
Connecticut
-$5.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$5.67M -$29.5K -584 -0.4%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$5.66M +$1.95M +38,650 +41%
SCM
28
Soleus Capital Management
Connecticut
$5.22M -$5.6M -110,800 -48%
Renaissance Technologies
29
Renaissance Technologies
New York
$5.17M +$1.47M +29,200 +32%
Marshall Wace
30
Marshall Wace
United Kingdom
$4.98M +$5.56M +110,120 +1,721%
American Century Companies
31
American Century Companies
Missouri
$4.82M +$5.71M +113,143 New
Deutsche Bank
32
Deutsche Bank
Germany
$3.73M +$3.84M +75,946 +663%
WCM Investment Management
33
WCM Investment Management
California
$3.59M +$44.7K +885 +1%
SI
34
Sofinnova Investments
California
$3.29M +$3.89M +77,100 New
Bank of America
35
Bank of America
North Carolina
$3.23M +$491K +9,728 +15%
VOYA Investment Management
36
VOYA Investment Management
Georgia
$3M – – –
Walleye Capital
37
Walleye Capital
New York
$2.89M +$2.97M +58,833 +668%
N
38
Nuveen
North Carolina
$2.87M +$92.4K +1,830 +3%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$2.69M -$141K -2,785 -4%
Goldman Sachs
40
Goldman Sachs
New York
$2.66M -$4.22M -83,562 -57%
SSA
41
Schonfeld Strategic Advisors
New York
$2.41M +$820K +16,245 +40%
Russell Investments Group
42
Russell Investments Group
United Kingdom
$2.37M +$726K +14,379 +35%
IHAM
43
Integral Health Asset Management
New York
$2.13M -$505K -10,000 -17%
CIBC Asset Management
44
CIBC Asset Management
Ontario, Canada
$2.02M -$2.16M -42,842 -48%
UOC
45
UBS O'Connor
Illinois
$1.94M +$2.3M +45,484 New
Qube Research & Technologies (QRT)
46
Qube Research & Technologies (QRT)
United Kingdom
$1.61M +$1.24M +24,631 +190%
Swiss National Bank
47
Swiss National Bank
Switzerland
$1.52M -$80.8K -1,600 -4%
UBS Group
48
UBS Group
Switzerland
$1.41M -$815K -16,128 -33%
DGM
49
Darwin Global Management
Jersey
$1.34M -$20.1M -397,146 -93%
D.E. Shaw & Co
50
D.E. Shaw & Co
New York
$1.33M +$1.57M +31,032 New
1
2
3 4 5

KROS Hedge Fund Activity: Q1 2023 in Review

129 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2023, worth a combined $937M — down 1.2% from $948M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new KROS positions and 17 closed out — a net gain of 3 holders — while 50 added to existing stakes and 33 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $47M. The largest seller was Darwin Global Management, cutting an estimated $20.1M.

  • 129 institutional investors held Keros Therapeutics (KROS) as of Q1 2023, up from 126 in Q4 2022.
  • Funds reported $937M of Keros Therapeutics stock for Q1 2023, down 1.2% quarter-over-quarter.
  • 20 funds opened new Keros Therapeutics positions in Q1 2023 and 17 closed out, a net change of +3 holders.
  • The largest Keros Therapeutics buyer in Q1 2023 was Paradigm Biocapital Advisors, an estimated $47M added.
  • The largest Keros Therapeutics seller in Q1 2023 was Darwin Global Management, an estimated $20.1M sold.

Based on aggregated 13F filings for Q1 2023.